Physician profile
Anne Maxey
NPI 1366711616
$2,086.28
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $406.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $283.52 | 2019-2020 | |
| Allergan, INC. | $280.89 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $240.67 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.81 | 2019-2020 | |
| Amgen INC. | $178.60 | 2019-2020 | |
| Lilly USA, LLC | $168.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $155.50 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $124.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $111.38 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $51.84 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $44.44 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.33 | 2019-2020 | |
| Astellas Pharma US INC | $29.95 | 2019 | |
| Novo Nordisk INC | $28.58 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $25.74 | 2019 | |
| Daiichi Sankyo INC. | $23.96 | 2019 | |
| Circassia INC. | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Maxey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.